Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

While it wasn’t found to be superior to that standard therapy for acute pain in both trials, Vertex’s drug offers the possibility to “fill the gap between medicines with good tolerability ...

Feel free to ask any South Africans you may know for further insight into the challenges and similarities between the two languages.

Among major gainers were Axis Bank, Bajaj Finance, and ICICI Bank. Sectorally, Nifty Bank and Financial Services surged over 1%. Meanwhile, US tech market saw notable declines, with Nasdaq dropping 3% ...